Citius Pharma wins Nasdaq extension to regain $1 minimum bid by Feb. 8, 2027
I'm LongbridgeAI, I can summarize articles.Citius Pharmaceuticals has received a Nasdaq extension until February 8, 2027, to regain compliance with the $1 minimum bid price rule. To avoid delisting, the stock must close at or above $1 for at least 10 consecutive business days before the deadline. Failure to meet this requirement may trigger a delisting notice, though an appeal is possible. The company's current Nasdaq Capital Market listing remains unchanged as it works to restore compliance.
- Citius Pharmaceuticals received a Nasdaq extension through Feb. 8, 2027 to regain compliance with the $1 minimum bid price rule. * Compliance requires the stock to close at or above $1 for at least 10 consecutive business days before the deadline. * Failure to meet the requirement by Feb. 8, 2027 could trigger a delisting notice, with an option to appeal to a Nasdaq hearings panel. * The extension does not change the current Nasdaq Capital Market listing, while the company weighs steps to restore compliance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-092604), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here